Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis.
Frequent but nonspecific venous narrowing in paediatric multiple sclerosis.
Slowing of brain atrophy and reductions in new multiple sclerosis lesions sustained at three years in patients treated with Genzyme's LemtradaTM
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.
A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
Food and Drug Administration briefing document for ofatumumab
Energy Cost of Walking and Its Association With Gait Parameters, Daily Activity, and Fatigue in Persons With Mild Multiple Sclerosis.
Infectious causes of multiple sclerosis.
No Regional Gray Matter Atrophy Differences between Pediatric- and Adult-Onset Relapsing-Remitting Multiple Sclerosis.
Pathogenesis of multiple sclerosis via environmental and genetic dysregulation of N-glycosylation.
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
Effects of exercise in experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis).
Moving towards the pan-European unification of Multiple Sclerosis Nurses: a consensus paper.
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis.
Immunohistochemical detection of sphingosine-1-phosphate and sphingosine kinase-1 in human tissue samples.
The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark.
Memory rehabilitation for people with multiple sclerosis.
The "liberation procedure" for multiple sclerosis: sacrificing science at the altar of consumer demand.
Multiple sclerosis: Spinal cord grey matter loss correlates with disability in MS.
Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man.
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
A gender-related action of IFNbeta-therapy was found in multiple sclerosis.
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.
Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.

Pages